Taro Pharmaceutical Industries Ltd. (TARO)

TARO Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	362.91	362.91	154.5	251.13	605.18	513.35
Short-Term Investments	516.44	516.44	695.79	569.61	418.48	595.38
Cash & Cash Equivalents	879.35	879.35	850.29	820.75	1,024	1,109
Cash Growth	3.42%	3.42%	3.60%	-19.82%	-7.67%	5.66%
Receivables	219.24	219.24	259.47	306.7	266.89	270.79
Inventory	204.82	204.82	226.67	210.44	180.29	153.07
Total Current Assets	1,303	1,303	1,336	1,338	1,471	1,533
Property, Plant & Equipment	217.59	217.59	190.14	199.69	205.51	209.96
Long-Term Investments	457.99	457.99	404.9	435.19	557.21	459.64
Goodwill and Intangibles	17.23	17.23	17.23	11.82	7.19	0
Other Long-Term Assets	165.85	165.85	186.82	191.78	166.13	139.05
Total Long-Term Assets	858.67	858.67	799.09	838.48	936.04	808.65
Total Assets	2,162	2,162	2,136	2,176	2,407	2,341
Accounts Payable	44.66	44.66	68.48	68.23	61.17	28.86
Other Current Liabilities	316.44	316.44	317.06	363.89	615.14	193.87
Total Current Liabilities	361.11	361.11	385.55	432.12	676.3	222.73
Other Long-Term Liabilities	7.96	7.96	19.11	32.8	35.12	8.76
Total Long-Term Liabilities	7.96	7.96	19.11	32.8	35.12	8.76
Total Liabilities	369.06	369.06	404.65	464.92	711.42	231.49
Retained Earnings	-	-	2,414	2,389	2,339	2,725
Comprehensive Income	0	0	0	-168.97	-151.62	-163.04
Shareholders' Equity	1,793	1,793	1,731	1,711	1,704	2,104
Net Cash / Debt	879.35	879.35	850.29	820.75	1,024	1,109
Net Cash / Debt Growth	3.42%	3.42%	3.60%	-19.82%	-7.67%	5.66%
Net Cash Per Share	23.40	23.40	22.62	21.80	26.79	28.83
Working Capital	942.3	942.3	950.88	905.77	794.53	1,310
Book Value Per Share	47.70	47.70	46.05	45.47	44.59	54.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).